Skip to main content
×
×
Home

Raising Standards While Watching the Bottom Line Making a Business Case for Infection Control

  • Eli N. Perencevich (a1) (a2), Patricia W. Stone (a3), Sharon B. Wright (a4), Yehuda Carmeli (a5), David N. Fisman (a6) (a7) and Sara E. Cosgrove (a8)...
Abstract

While society would benefit from a reduced incidence of nosocomial infections, there is currently no direct reimbursement to hospitals for the purpose of infection control, which forces healthcare institutions to make economic decisions about funding infection control activities. Demonstrating value to administrators is an increasingly important function of the hospital epidemiologist because healthcare executives are faced with many demands and shrinking budgets. Aware of the difficulties that face local infection control programs, the Society for Healthcare Epidemiology of America (SHEA) Board of Directors appointed a task force to draft this evidence-based guideline to assist hospital epidemiologists in justifying and expanding their programs. In Part 1, we describe the basic steps needed to complete a business-case analysis for an individual institution. A case study based on a representative infection control intervention is provided. In Part 2, we review important basic economic concepts and describe approaches that can be used to assess the financial impact of infection prevention, surveillance, and control interventions, as well as the attributable costs of specific healthcare-associated infections. Both parts of the guideline aim to provide the hospital epidemiologist, infection control professional, administrator, and researcher with the tools necessary to complete a thorough business-case analysis and to undertake an outcome study of a nosocomial infection or an infection control intervention.

Copyright
Corresponding author
Department of Epidemiology and Preventive Medicine, University of Maryland School of Medicine, Associate Hospital Epidemiologist, University of Maryland Medical Center, 100 N. Greene St., Lower Level, Baltimore, MD 21201 (eperence@epi.umaryland.edu)
References
Hide All
1. Casalino LP. Markets and medicine: barriers to creating a “business case for quality.” Perspect Biol Med 2003;46:3851.
2. Murphy DM. From expert data collectors to interventionists: changing the focus for infection control professionals. Am J Infect Control 2002;30:120132.
3. Burke JP. Infection control—a problem for patient safety. New Engl J Med 2003;348:651656.
4. Calfee DP, Farr BM. Infection control and cost control in the era of managed care. Infect Control Hosp Epidemiol 2002;23:407410.
5. Murphy DM, Alvarado CI, Fawal H. The business of infection control and epidemiology. Am J Infect Control 2002;30:7576.
6. Wright SB, Ostrowsky B, Fishman N, et al. Hospital epidemiology and infection control roles expanding despite limited resources and compensation. In: Program and abstracts of the 17th Annual Scientific Meeting of the Society for Healthcare Epidemiology in America (Baltimore). 2007 (Abstract 55).
7. Heffler S, Smith S, Keehan S, Borger C, Clemens MK, Truffer C. US health spending projections for 2004-2014. Health Aff (Millwood) 2005;suppl Web exclusives:W5-74-W5-85.
8. Stone PW, Schackman BR, Neukermans CP, et al. A synthesis of cost-utility analysis literature in infectious disease. Lancet Infect Dis 2005;5:383391.
9. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 7th ed. Oxford: Oxford University Press;2005.
10. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. 1st ed. New York, NY: Oxford University Press;1996.
11. Petitti DB. Meta-analysis, Decision Analysis, and Cost-Effectiveness Analysis. 2nd ed. New York: Oxford University Press;2000.
12. Leatherman S, Berwick D, Iles D, et al. The business case for quality: case studies and an analysis. Health Aff (Millwood) 2003;22:1730.
13. Stone PW, Braccia D, Larson E. Systematic review of economic analyses of health care-associated infections. Am J Infect Control 2005;33:501509.
14. Mansley EC, McKenna MT. Importance of perspective in economic analyses of cancer screening decisions. Lancet 2001;358:11691173.
15. McGregor JC, Weekes E, Forrest GN, et al. Impact of a computerized clinical decision support system on reducing inappropriate antimicrobial use: a randomized controlled trial. J Am Med Inform Assoc 2006;13:378384.
16. Harris AD, Bradham DD, Baumgarten M, Zuckerman IH, Fink JC, Perencevich EN. The use and interpretation of quasi-experimental studies in infectious diseases. Clin Infect Dis 2004;38:15861591.
17. 2006 APIC Member Salary and Career Survey. Available at: http://www.apic.org/Content/NavigationMenu/MemberServices/2006SalarySurveyResults/2006_Salary_Survey.htm. Accessed September 1, 2006.
18. McConkey SJ, L'Ecuyer PB, Murphy DM, Leet TL, Sundt TM, Fraser VJ. Results of a comprehensive infection control program for reducing surgical-site infections in coronary artery bypass surgery. Infect Control Hosp Epidemiol 1999;20:533538.
19. Dietrich ES, Demmler M, Schulgen G, et al. Nosocomial pneumonia: a cost-of-illness analysis. Infection 2002;30:6167.
20. Hugonnet S, Eggimann P, Borst F, Maricot P, Chevrolet JC, Pittet D. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. Infect Control Hosp Epidemiol 2004;25:10901096.
21. Warren DK, Shukla SJ, Olsen MA, et al. Outcome and attributable cost of ventilator-associated pneumonia among intensive care unit patients in a suburban medical center. Crit Care Med 2003;31:13121317.
22. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002;122:21152121.
23. Safdar N, Dezfulian C, Collard HR, Saint S. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med 2005;33:21842193.
24. Blot SI, Depuydt P, Annemans L, et al. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 2005;41:15911598.
25. Digiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999;160:976981.
26. Rello J, Ochagavia A, Sabanes E, et al. Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med 2000;162:10271030.
27. Coello R, Charlett A, Wilson J, Ward V, Pearson A, Bordello P. Adverse impact of surgical site infections in English hospitals. J Hosp Infect 2005;60:93103.
28. Coskun D, Aytac J, Aydinli A, Bayer A. Mortality rate, length of stay and extra cost of sternal surgical site infections following coronary artery bypass grafting in a private medical centre in Turkey. J Hosp Infect 2005;60:176179.
29. Hollenbeak CS, Murphy DM, Koenig S, Woodward RS, Dunagan WC, Fraser VJ. The clinical and economic impact of deep chest surgical site infections following coronary artery bypass graft surgery. Chest 2000;118:397402.
30. Jenney AW, Harrington GA, Russo PL, Spelman DW. Cost of surgical site infections following coronary artery bypass surgery. ANZ J Surg 2001;71:662664.
31. Tambyah PA, Knasinski V, Maki DG. The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care. Infect Control Hosp Epidemiol 2002;23:2731.
32. Lai KK, Fontecchio SA. Use of silver-hydrogel urinary catheters on the incidence of catheter-associated urinary tract infections in hospitalized patients. Am J Infect Control 2002;30:221225.
33. Dimick JB, Weeks WB, Karia RJ, Das S, Campbell DA Jr. Who pays for poor surgical quality? Building a business case for quality improvement. J Am Coll Surg 2006;202:933937.
34. Ward WJ Jr, Spragens L, Smithson K. Building the business case for clinical quality. Healthc Financ Manage 2006;60:9298.
35. Roberts RR, Frutos PW, Ciavarella GG, et al. Distribution of variable vs fixed costs of hospital care. JAMA 1999;281:644649.
36. US Department of Health and Human Services, Centers for Medicare and Medicaid Services. Medicare and Medicaid statistical supplement: details for Medicare short-stay hospitals. Available at: http://www.cms.hhs.gov. Accessed July 17, 2007.
37. Wright MO, Hebden JN, Harris AD, et al. Aggressive control measures for resistant Acinetobacter haumannii and the impact on acquisition of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a medical intensive care unit. Infect Control Hosp Epidemiol 2004;25:167168.
38. Guinan JL, McGuckin M, Shubin A, Tighe J. A descriptive review of malpractice claims for health care-acquired infections in Philadelphia. Am J Infect Control 2005;33:310312.
39. Julian KG, Brumbach AM, Chicora MK, et al. First year of mandatory reporting of healthcare-associated infections, Pennsylvania: an infection control-chart abstractor collaboration. Infect Control Hosp Epidemiol 2006;27:926930.
40. Lindenauer PK, Remus D, Roman S, et al. Public reporting and pay for performance in hospital quality improvement. New Engl J Med 2007;356:486496.
41. Perencevich EN, Fisman DN, Lipsitch M, Harris AD, Morris JG Jr, Smith DL. Projected benefits of active surveillance for vancomycin-resistant enterococci in intensive care units. Clin Infect Dis 2004;38:11081115.
42. Ginter PM, Swayne LE, Duncan WJ. Strategic Management of Health Care Organizations. 4thed. Maiden, MA: Blackwell Publishing Ltd.;2002.
43. Dooley RS, Fryxell GE, Judge WQ. Belaboring the not-so-obvious: consensus, commitment, and strategy implementation speed and success. J Management 2000;26:12371257.
44. Zanetti G, Goldie SJ, Piatt R. Clinical consequences and cost of limiting use of vancomycin for perioperative prophylaxis: example of coronary artery bypass surgery. Emerg Infect Dis 2001;7:820827.
45. Neumann PJ. Using Cost-Effectiveness Analysis to Improve Health Care. 1st ed. New York, NY: Oxford University Press;2005.
46. Koplan JP, Harpaz R. Shingles vaccine: effective and costly or cost-effective? Ann Intern Med 2006;145:386387.
47. World Health Organization (WHO). Choosing interventions that are cost effective (WHO-CHOICE) 2006. Available at: http://www.who.int/choice/costs/CER_levels/en/index.html. Accessed September 7, 2006.
48. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ 2006;332:699703.
49. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index, 2006. Available at: http://www.bls.gov/cpi/home.htm. Accessed April 29, 2007.
50. US Department of Labor, Bureau of Labor Statistics. Consumer Price Index inflation calculator. Available at: http://data.bls.gov/cgi-bin/cpicalc.pl. Accessed April 29, 2007.
51. US Department of Labor, Bureau of Labor Statistics (BLS). How BLS measures price change for medical care services in the Consumer Price Index. March 1, 2007. Available at: http://www.bls.gov/cpi/cpifact4.htm. Accessed April 29, 2007.
52. Keeler E, Cretin S. Discounting of life-savings and other non-monetary effects. Management Sei 1983;29:300306.
53. Engemann JJ Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592598.
54. Kaye KS, Engemann JJ, Mozaffari E, Carmeli Y. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis 2004;10:11251128.
55. Schulgen G, Kropec A, Kappstein I, Daschner F, Schumacher M. Estimation of extra hospital stay attributable to nosocomial infections: heterogeneity and timing of events. J Clin Epidemiol 2000;53:409417.
56. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818829.
57. Iezzoni LI. The risks of risk adjustment. JAMA 1997;278:16001607.
58. Robins JM. The control of confounding by intermediate variables. Stat Med 1989;8:679701.
59. Perencevich EN. Excess shock and mortality in Staphylococcus aureus related to methicillin resistance. Clin Infect Dis 2000;31:13111313.
60. Schwaber MJ, Carmeli Y. Antimicrobial resistance and patient outcomes: the hazards of adjustment. Crit Care 2006;10:164.
61. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373383.
62. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992;45:197203.
63. Batista R, Kaye K, Yokoe DS. Admission-specific chronic disease scores as alternative predictors of surgical site infection for patients undergoing coronary artery bypass graft surgery. Infect Control Hosp Epidemiol 2006;27:802808.
64. Kaye KS, Sands K, Donahue JG, Chan KA, Fishman P, Platt R. Preoperative drug dispensing as predictor of surgical site infection. Emerg Infect Dis 2001;7:5765.
65. McGregor JC, Kim PW, Perencevich EN, et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am J Epidemiol 2005;161:483493.
66. McGregor JC, Perencevich EN, Furuno JP, et al. Comorbidity risk-adjustment measures were developed and validated for studies of antibiotic-resistant infections. J Clin Epidemiol 2006;59:12661273.
67. Perencevich EN, Sands KE, Cosgrove SE, Guadagnoli E, Meara E, Piatt R. Health and economic impact of surgical site infections diagnosed after hospital discharge. Emerg Infect Dis 2003;9:196203.
68. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;36:14331437.
69. Haley RW. Measuring the costs of nosocomial infections: methods for estimating economic burden on the hospital. Am J Med 1991;91:32S38S.
70. Finkler SA. The distinction between cost and charge. Ann Intern Med 1982;96:102109.
71. Pronovost P, Angus DC. Cost reduction and quality improvement: it takes two to tango. Crit Care Med 2000;28:581583.
72. Howard D, Cordell R, McGowan JE Jr, Packard RM, Scott RD 2nd, Solomon SL. Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention-Emory Workshop. Clin Infect Dis 2001;33:15731578.
73. Ashby J. The accuracy of cost measures derived from Medicare cost report data, Intramural #1-93-01. Prospective Payment Assessment Commission. Washington, DC, 1993.
74. Shwartz M, Young DW, Siegrist R. The ratio of costs to charges: how good a basis for estimating costs? Inquiry 1995;32:476481.
75. Economic Research Federal Reserve Bank of St. Louis. Federal Reserve Economic Database II. Available at: http://research.stlouisfed.org/fred2/categories/15. Accessed April 29, 2007.
76. Larson E. State-of-the-science—2004: time for a “no excuses/no tolerance” (NET) strategy. Am J Infect Control 2005;33:548557.
77. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. New Engl J Med 1992;326:281286.
78. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. Neyv Engl J Med 2000;342:18781886.
79. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New Engl J Med 2000;342:18871892.
80. Pocock SJ, Elbourne DR. Randomized trials or observational tribulations? New Engl J Med 2000;342:19071909.
81. Hayes RJ, Alexander ND, Bennett S, Cousens SN. Design and analysis issues in cluster-randomized trials of interventions against infectious diseases. Stat Methods Med Res 2000;9:95116.
82. Klar N, Donner A. Current and future challenges in the design and analysis of cluster randomization trials. Stat Med 2001;20:37293740.
83. Medical Research Council. Cluster randomized trials: methodological and ethical considerations. MRS Clinical Trials Series, 2002. Available at: http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d= MRC002406. Accessed April 30, 2007.
84. Bennett S, Parpia T, Hayes R, Cousens S. Methods for the analysis of incidence rates in cluster randomized trials. Int J Epidemiol 2002;31:839846.
85. Donner A, Klar N. Pitfalls of and controversies in cluster randomization trials. Am J Public Health 2004;94:416422.
86. Elbourne DR, Campbell MK. Extending the CONSORT statement to cluster randomized trials: for discussion. Stat Med 2001;20;489496.
87. Muto CA, Giannetta ET, Durbin LJ, Simonton BM, Farr BM. Cost-effectiveness of perirectal surveillance cultures for controlling vancomycin-resistant Enterococcus . Infect Control Hosp Epidemiol 2002;23:429435.
88. Rao N, Jacobs S, Joyce L. Cost-effective eradication of an outbreak of methicillin-resistant Staphylococcus aureus in a community teaching hospital. Infect Control Hosp Epidemiol 1988;9:255260.
89. Shadish WR, Cook TD, Campbell DT. Experimental and Quasi-experimental Designs for Generalized Causal Inference. Boston: Houghton Mifflin Company;2002.
90. Harris AD, Lautenbach E, Perencevich E. A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. Clin Infect Dis 2005;41:7782.
91. Shadish WR, Heinsman DT. Experiments versus quasi-experiments: do they yield the same answer? NIDA Res Monogr 1997;170:147164.
92. Austin DJ, Bonten MJ, Weinstein RA, Slaughter S, Anderson RM. Vancomycin-resistant enterococci in intensive-care hospital settings: transmission dynamics, persistence, and the impact of infection control programs. Proc Natl Acad Sci USA 1999;96:69086913.
93. Bergstrom CT, Lo M, Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci USA 2004;101:1328513290.
94. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 1997;94:1210612111.
95. Bootsma MC, Diekmann O, Bonten MJ. Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. Proc Natl Acad Sci USA 2006;103:56205625.
96. Lipsitch M, Cohen T, Cooper B, et al. Transmission dynamics and control of severe acute respiratory syndrome. Science 2003;300:19661970.
97. Perencevich EN, Hartley DM. Of models and methods: our analytic armamentarium applied to methicillin-resistant Staphylococcus aureus . Infect Control Hosp Epidemiol 2005;26:594597.
98. Ostrowsky B, Steinberg JT, Farr B, Sohn AH, Sinkowitz-Cochran RL, Jarvis WR. Reality check: should we try to detect and isolate vancomycin-resistant enterococci patients? Infect Control Hosp Epidemiol 2001;22:116119.
99. Hunink M, Glasziou P, Siegel J, et al. Decision Making in Health and Medicine. 1st ed. Cambridge, United Kingdom: Cambridge University Press;2001.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Infection Control & Hospital Epidemiology
  • ISSN: 0899-823X
  • EISSN: 1559-6834
  • URL: /core/journals/infection-control-and-hospital-epidemiology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 29 *
Loading metrics...

Abstract views

Total abstract views: 567 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 17th January 2018. This data will be updated every 24 hours.